Loading organizations...
§ Private Profile · Seattle, WA, USA
Biotechnology company developing AI-designed multifunctional protein therapeutics for complex diseases.
Accipiter Biosciences is a Seattle, Washington-based biotechnology company that develops artificial intelligence-designed de novo proteins capable of binding to multiple cellular targets simultaneously to treat complex human diseases and conditions. Originating from the University of Washington’s Institute for Protein Design led by Nobel laureate David Baker, the enterprise utilizes advanced computational biology to pioneer multifunctional protein therapeutics. The startup emerged from stealth in November 2025 after securing $12.7 million in seed funding through an equity financing round co-led by Takeda Ventures and Flying Fish Partners, building upon a previously disclosed $7.9 million raise. To further advance its pipeline of novel biological treatments, the firm has established strategic development partnerships with major pharmaceutical corporations including Pfizer and Kite Pharma. Accipiter Biosciences was founded in 2023 by Matthew Bick, Javier Castellanos, Hector Rincon-Arano, and Bill Arthur.
Accipiter Biosciences has raised $12.7M across 1 funding round.
Accipiter Biosciences has raised $12.7M in total across 1 funding round.
Accipiter Biosciences has raised $12.7M in total across 1 funding round.
Accipiter Biosciences's investors include Flying Fish Partners, Takeda.
Accipiter Biosciences has raised $12.7M across 1 funding round. Most recently, it raised $12.7M Seed in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 7, 2025 | $12.7M Seed | Flying Fish Partners, Takeda | — | Announced |